3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
12
Neoplasm Metastasis
3
Stomach Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Neoplasms
1
HER2-positive Gastric Cancer
1
HER2-Positive Primary Breast Cancer
1
Carcinoma, Ovarian Epithelial
1
Breast Diseases
1
Brain Neoplasms
1
Biliary Tract Neoplasms
1
Anatomic Stage IV Breast Cancer AJCC v8
1
Adenocarcinoma
1
Interventions
Paclitaxel
79
Carboplatin
64
Bevacizumab
33
liposomal doxorubicin
29
Topotecan
28
Gemcitabine
25
Cisplatin
19
olaparib
18
Drug Therapy
12
Doxorubicin
12
Taxes
11
niraparib
9
Docetaxel
6
CP protocol
6
Trabectedin
5
Hyperthermic Intraperitoneal Chemotherapy
5
Etoposide
5
Cyclophosphamide
5
1-dodecylpyridoxal
5
rucaparib
4
pembrolizumab
4
avelumab
4
atezolizumab
4
Immunoglobulin G
4
Ifosfamide
4
Disulfides
4
Dexamethasone
4
Chemotherapy, Adjuvant
4
trebananib
3
fluzoparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Ovarian Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT06819007
2026-05-26
DO-01
Daiichi Sankyo
Phase 3
Recruiting
582 enrolled